Trial | NCT00830609  Report issue

Title

High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
Effect of High Dose vs. Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3, High Viral Load Without Rapid Virological Response

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    101
The rate of sustained virological response (SVR) in patients with chronic hepatitis C, genotype 3, high viral load and without rapid virological response (RNA-HCV negative at week 4) is low. Standard of care of these patients include treatment with weekly peginterferon plus 800 mg/day of ribavirin (RBV). Extended treatment to 48 weeks does not provide more clinical benefit than the standard duration. The main hypothesis is that higher dose of ribavirin may be better in terms of SVR than the standard dose.
Aims:

Efficacy 1.1) Rate of RNA-HCV negative at week 4 and 24 in each arm. 1.2) Rate of SVR in each arm.
Safety 2.1) Rate of adverse effects in each arm.

Design: Randomized controlled trial.

Patients will be randomly allocated into three arms:

Arm A : Peginterferon α-2a (180 μg/week)SC. plus Ribavirin (800 mg/day) p.o. over 24 weeks.

Arm B: Peginterferon α-2a (180 μg/week) plus Ribavirin (1600 mg/day) with support of Epoetin β (450 IU/kg/week) SC over 4 weeks:

B1.- If RNA-HCV undetectable at week 4, standard of care will be continued (Peginterferon α-2a, 180 μg/wee plus Ribavirin (800 mg/day) over 20 additional weeks).

B2.- If RNA-HCV were detectable at week 4, treatment will be continued with peginterferon α-2a (180 μg/week) plus RBV(1,600 mg/day) plus Epoetin β (450 UI/kg/week) over 20 additional weeks.

Sample size: 111 patients. To increase the SVR from 50% to 75%. Beta: 0.1; alfa: 0.05; Loss: 15%.

Randomization will be 1:2, 37 patients in Group A and 74 patients in group B.
Study Started
Nov 30
2008
Primary Completion
Sep 30
2011
Study Completion
Dec 31
2011
Last Update
Mar 13
2012
Estimate

Drug Peginterferon alfa 2 A

Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)

  • Other names: Pegasys

Drug Peginterferon alfa 2 A, ribavirin + Epo Beta

Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks

  • Other names: Pegasys

Drug ribavirin

RBV 1600 mg/day 24 weeks

  • Other names: Epoetin beta, peginterferon alfa 2 a

Drug ribavirin

ribavirin 800 mg/day for 24 weeks

  • Other names: Pegasys

Drug Peginterferon alfa 2

Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks

  • Other names: Pegasys

Drug ribavirin

RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks

  • Other names: Pegasys

A Active Comparator

Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).

B1 Experimental

After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.

B2 Experimental

If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.

Criteria 

Inclusion Criteria:

HCV Genotype 3
RNA-HCV > > 600.000 IU/ml.
Compromise to use contraceptive measures on treatment until 6 months after the end of treatment.

Exclusion Criteria:

Pregnant or breastfeeding females.
Concurrent treatment with antineoplastic or immunomodulatory agents, including corticosteroids or radiation therapy over the last 6 months before starting the trial
Treatment with investigational drugs < 6 weeks before starting the trial
Chronic liver disease other than hepatitis C.
Evidence of hepatocellular carcinoma.
Evidence of carcinoma hepatocellular
Decompensated liver disease
Baseline Neutrophil count < 1500/cc; or Platelet count < 90,000/cc
Baseline Hemoglobin <12 g/dL in females o <13 g/dL in males.
Increased risk of anemia(Eg, thalassemia, spherocytosis..).
Ischemic heart disease or cerebrovascular disease.
Serum creatinine >1.5 times upper limit of normality.
History of severe psychiatric conditions (Major antidepressives or neuroleptic drugs required for major depression or psychosis), suicide attempts or psychiatric disability .
History of convulsive disorders.
Immunological conditions.
Chronic Obstructive Lung Disease with limited functionality
Severe heart disease or congestive cardiac insufficiency cardiopathy grave.
Advanced atherosclerosis
Solid organ or bone marrow transplant.
No Results Posted